2 min read

Bitcoin Cash and Bitcoin SV Rise as CME Plans BCH Futures

Bitcoin Cash rallied alongside a preliminary Grayscale filing, while Bitcoin closed at $85,928.46 on Sept. 23 after reaching a Sept. 21 high of $87,363.76.

Mentioned assets
Two metallic coins beside a brass futures exchange bell / TokenPost.ai
Two metallic coins beside a brass futures exchange bell / TokenPost.ai

Bitcoin Cash (BCH) and Bitcoin SV (BSV) advanced as Bitcoin (BTC) pulled back from a Sept. 21 high, with planned BCH futures and a preliminary ETF filing adding new developments for the forked assets.

CME Group plans to launch Bitcoin Cash and Uniswap futures on Oct. 19, pending regulatory review. Standard Bitcoin Cash futures contracts would represent 250 BCH, while Micro Bitcoin Cash futures would represent 25 BCH.

The contracts are designed to provide tools for price discovery, risk management and exposure through CME’s regulated, 24/7 marketplace.

“As crypto markets continue to mature, participants require broader, regulated tools to navigate evolving digital asset related price risk,” said Giovanni Vicioso, CME Group’s global head of cryptocurrency products.

Grayscale filed a preliminary prospectus Sept. 11 describing plans to rename its Bitcoin Cash Trust as Grayscale Bitcoin Cash Trust ETF in connection with a proposed NYSE Arca listing. The filing says the trust’s investment objective would be to reflect the value of the BCH it holds, less expenses and liabilities.

Neither development is final. CME’s futures launch remains subject to regulatory review, and the Grayscale filing describes a proposed listing rather than an established ETF.

Bitcoin SV traded between $18.37 and $21.60 during the Sept. 22–23 daily period before closing at $20.82. The token rose alongside BCH.

Bitcoin Cash split from Bitcoin in August 2017 after a dispute over block size. Bitcoin SV later split from Bitcoin Cash during the 2018 “Hash War.”

Bitcoin closed at $85,928.46 on Sept. 23, below its Sept. 21 daily high of $87,363.76. The planned CME products are scheduled for Oct. 19, subject to regulatory review.

Loading…